| Year |
Citation |
Score |
| 2021 |
Chan P, Ding HT, Liederer BM, Mao J, Belloni P, Chen L, Gao SS, Joseph V, Yang X, Lin JS, Mitra MS, Putnam WS, Quartino A, Bauer RN, Pan L. Translational and pharmacokinetic-pharmacodynamic application for the clinical development of GDC-0334, a novel TRPA1 inhibitor. Clinical and Translational Science. PMID 34058071 DOI: 10.1111/cts.13049 |
0.331 |
|
| 2019 |
Hamilton GL, Chen H, Deshmukh G, Eigenbrot C, Fong R, Johnson A, Kohli PB, Lupardus PJ, Liederer BM, Ramaswamy S, Wang H, Wang J, Xu Z, Zhu Y, Vucic D, et al. Potent and selective inhibitors of receptor-interacting protein kinase 1 that lack an aromatic back pocket group. Bioorganic & Medicinal Chemistry Letters. PMID 31000154 DOI: 10.1016/J.Bmcl.2019.04.014 |
0.329 |
|
| 2018 |
Liederer BM, Cheong J, Chou KJ, Dragovich PS, Le H, Liang X, Ly J, Mukadam S, Oeh J, Sampath D, Wang L, Wong S. Preclinical Assessment of the ADME, Efficacy and Drug-Drug Interaction Potential of a Novel NAMPT Inhibitor. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-56. PMID 30257601 DOI: 10.1080/00498254.2018.1528407 |
0.391 |
|
| 2018 |
Daemen A, Liu B, Song K, Kwong M, Gao M, Hong R, Nannini M, Peterson D, Liederer BM, de la Cruz C, Sangaraju D, Jaochico A, Zhao X, Sandoval W, Hunsaker T, et al. Pan-Cancer Metabolic Signature Predicts Co-Dependency on Glutaminase and De Novo Glutathione Synthesis Linked to a High-Mesenchymal Cell State. Cell Metabolism. PMID 30043751 DOI: 10.1016/J.Cmet.2018.06.003 |
0.341 |
|
| 2018 |
Durk MR, Deshmukh G, Valle N, Ding X, Liederer BM, Liu X. Use of Subcutaneous and Intraperitoneal Administration Methods to Facilitate Cassette Dosing in Microdialysis Studies in Rats. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 29700231 DOI: 10.1124/Dmd.118.080697 |
0.341 |
|
| 2017 |
Liang J, Labadie S, Zhang B, Ortwine DF, Patel S, Vinogradova M, Kiefer JR, Mauer T, Gehling VS, Harmange JC, Cummings R, Lai T, Liao J, Zheng X, Liu Y, ... ... Liederer BM, et al. From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors. Bioorganic & Medicinal Chemistry Letters. PMID 28512031 DOI: 10.1016/J.Bmcl.2017.05.016 |
0.329 |
|
| 2017 |
Wong H, Bohnert T, Damian-Iordache V, Gibson C, Hsu CP, Krishnatry AS, Liederer BM, Lin J, Lu Q, Mettetal JT, Mudra DR, Nijsen MJMA, Schroeder P, Schuck E, Suryawanshi S, et al. Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective. Drug Discovery Today. PMID 28476536 DOI: 10.1016/J.Drudis.2017.04.015 |
0.664 |
|
| 2016 |
Misner DL, Kauss MA, Singh J, Uppal H, Bruening-Wright A, Liederer BM, Lin T, McCray B, La N, Nguyen T, Sampath D, Dragovich PS, O'Brien T, Zabka TS. Cardiotoxicity Associated with Nicotinamide Phosphoribosyltransferase Inhibitors in Rodents and in Rat and Human-Derived Cells Lines. Cardiovascular Toxicology. PMID 27783203 DOI: 10.1007/S12012-016-9387-6 |
0.341 |
|
| 2016 |
Zak M, Yuen PW, Liu X, Patel S, Sampath D, Oeh J, Liederer BM, Wang W, O'Brien T, Xiao Y, Skelton N, Hua R, Sodhi J, Wang Y, Zhang L, et al. Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors. Journal of Medicinal Chemistry. PMID 27541271 DOI: 10.1021/Acs.Jmedchem.6B00697 |
0.341 |
|
| 2016 |
Liang J, Zhang B, Labadie S, Ortwine DF, Vinogradova M, Kiefer JR, Gehling VS, Harmange JC, Cummings R, Lai T, Liao J, Zheng X, Liu Y, Gustafson A, Van der Porten E, ... ... Liederer BM, et al. Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies. Bioorganic & Medicinal Chemistry Letters. PMID 27406798 DOI: 10.1016/J.Bmcl.2016.06.078 |
0.356 |
|
| 2016 |
Zabka T, Kim A, Uppal H, Kauss A, Dhawan P, Liederer B, Lin T, McCray B, Nguyen T, Chou C, Misner D. Considerations for in vitro systems to reflect in vivo toxicities to facilitate drug development Journal of Pharmacological and Toxicological Methods. 81: 361. DOI: 10.1016/J.Vascn.2016.02.087 |
0.316 |
|
| 2015 |
Deshmukh G, Sun K, Liederer BM, Ding X, Liu X. Use of cassette dosing to enhance the throughput of rat brain microdialysis studies. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 43: 1123-8. PMID 25943358 DOI: 10.1124/Dmd.115.064204 |
0.31 |
|
| 2015 |
Schuck E, Bohnert T, Chakravarty A, Damian-Iordache V, Gibson C, Hsu CP, Heimbach T, Krishnatry AS, Liederer BM, Lin J, Maurer T, Mettetal JT, Mudra DR, Nijsen MJ, Raybon J, et al. Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape. The Aaps Journal. 17: 462-73. PMID 25630504 DOI: 10.1208/S12248-014-9716-2 |
0.66 |
|
| 2015 |
Poulin P, Chen YH, Ding X, Gould SE, Hop CE, Messick K, Oeh J, Liederer BM. Prediction of drug distribution in subcutaneous xenografts of human tumor cell lines and healthy tissues in mouse: application of the tissue composition-based model to antineoplastic drugs. Journal of Pharmaceutical Sciences. 104: 1508-21. PMID 25615572 DOI: 10.1002/Jps.24336 |
0.351 |
|
| 2015 |
Zak M, Liederer BM, Sampath D, Yuen PW, Bair KW, Baumeister T, Buckmelter AJ, Clodfelter KH, Cheng E, Crocker L, Fu B, Han B, Li G, Ho YC, Lin J, et al. Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility. Bioorganic & Medicinal Chemistry Letters. 25: 529-41. PMID 25556090 DOI: 10.1016/J.Bmcl.2014.12.026 |
0.341 |
|
| 2015 |
Zabka TS, Singh J, Dhawan P, Liederer BM, Oeh J, Kauss MA, Xiao Y, Zak M, Lin T, McCray B, La N, Nguyen T, Beyer J, Farman C, Uppal H, et al. Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase. Toxicological Sciences : An Official Journal of the Society of Toxicology. 144: 163-72. PMID 25505128 DOI: 10.1093/Toxsci/Kfu268 |
0.333 |
|
| 2014 |
Giannetti AM, Zheng X, Skelton NJ, Wang W, Bravo BJ, Bair KW, Baumeister T, Cheng E, Crocker L, Feng Y, Gunzner-Toste J, Ho YC, Hua R, Liederer BM, Liu Y, et al. Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT). Journal of Medicinal Chemistry. 57: 770-92. PMID 24405419 DOI: 10.1021/Jm4015108 |
0.335 |
|
| 2013 |
O'Brien T, Oeh J, Xiao Y, Liang X, Vanderbilt A, Qin A, Yang L, Lee LB, Ly J, Cosino E, LaCap JA, Ogasawara A, Williams S, Nannini M, Liederer BM, et al. Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models. Neoplasia (New York, N.Y.). 15: 1314-29. PMID 24403854 DOI: 10.1593/Neo.131718 |
0.328 |
|
| 2013 |
Xiao Y, Elkins K, Durieux JK, Lee L, Oeh J, Yang LX, Liang X, DelNagro C, Tremayne J, Kwong M, Liederer BM, Jackson PK, Belmont LD, Sampath D, O'Brien T. Dependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway renders them sensitive to NAMPT inhibition with GNE-618. Neoplasia (New York, N.Y.). 15: 1151-60. PMID 24204194 DOI: 10.1593/Neo.131304 |
0.318 |
|
| 2013 |
Zheng X, Bair KW, Bauer P, Baumeister T, Bowman KK, Buckmelter AJ, Caligiuri M, Clodfelter KH, Feng Y, Han B, Ho YC, Kley N, Li H, Liang X, Liederer BM, et al. Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT). Bioorganic & Medicinal Chemistry Letters. 23: 5488-97. PMID 24021463 DOI: 10.1016/J.Bmcl.2013.08.074 |
0.368 |
|
| 2013 |
Dragovich PS, Bair KW, Baumeister T, Ho YC, Liederer BM, Liu X, Liu Y, O'Brien T, Oeh J, Sampath D, Skelton N, Wang L, Wang W, Wu H, Xiao Y, et al. Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT). Bioorganic & Medicinal Chemistry Letters. 23: 4875-85. PMID 23899614 DOI: 10.1016/J.Bmcl.2013.06.090 |
0.311 |
|
| 2013 |
Poulin P, Dambach DM, Hartley DH, Ford K, Theil FP, Harstad E, Halladay J, Choo E, Boggs J, Liederer BM, Dean B, Diaz D. An algorithm for evaluating potential tissue drug distribution in toxicology studies from readily available pharmacokinetic parameters. Journal of Pharmaceutical Sciences. 102: 3816-29. PMID 23878104 DOI: 10.1002/Jps.23670 |
0.345 |
|
| 2013 |
Zheng X, Bauer P, Baumeister T, Buckmelter AJ, Caligiuri M, Clodfelter KH, Han B, Ho YC, Kley N, Lin J, Reynolds DJ, Sharma G, Smith CC, Wang Z, Dragovich PS, ... ... Liederer BM, et al. Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors. Journal of Medicinal Chemistry. 56: 6413-33. PMID 23859118 DOI: 10.1021/Jm4008664 |
0.338 |
|
| 2013 |
Gunzner-Toste J, Zhao G, Bauer P, Baumeister T, Buckmelter AJ, Caligiuri M, Clodfelter KH, Fu B, Han B, Ho YC, Kley N, Liang X, Liederer BM, Lin J, Mukadam S, et al. Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties. Bioorganic & Medicinal Chemistry Letters. 23: 3531-8. PMID 23668988 DOI: 10.1016/J.Bmcl.2013.04.040 |
0.33 |
|
| 2013 |
Poulin P, Hop CE, Salphati L, Liederer BM. Correlation of tissue-plasma partition coefficients between normal tissues and subcutaneous xenografts of human tumor cell lines in mouse as a prediction tool of drug penetration in tumors. Journal of Pharmaceutical Sciences. 102: 1355-69. PMID 23334959 DOI: 10.1002/Jps.23452 |
0.321 |
|
| 2013 |
Lin J, Sampath D, Nannini MA, Lee BB, Degtyarev M, Oeh J, Savage H, Guan Z, Hong R, Kassees R, Lee LB, Risom T, Gross S, Liederer BM, Koeppen H, et al. Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1760-72. PMID 23287563 DOI: 10.1158/1078-0432.Ccr-12-3072 |
0.335 |
|
| 2013 |
Liederer BM, Berezhkovskiy LM, Ubhayakar SS, Deng Y. An alternative approach for quantitative bioanalysis using diluted blood to profile oral exposure of small molecule anticancer drugs in mice. Journal of Pharmaceutical Sciences. 102: 750-60. PMID 23225118 DOI: 10.1002/Jps.23395 |
0.335 |
|
| 2013 |
Diaz D, Ford KA, Hartley DP, Harstad EB, Cain GR, Achilles-Poon K, Nguyen T, Peng J, Zheng Z, Merchant M, Sutherlin DP, Gaudino JJ, Kaus R, Lewin-Koh SC, Choo EF, ... Liederer BM, et al. Pharmacokinetic drivers of toxicity for basic molecules: strategy to lower pKa results in decreased tissue exposure and toxicity for a small molecule Met inhibitor. Toxicology and Applied Pharmacology. 266: 86-94. PMID 23142475 DOI: 10.1016/J.Taap.2012.10.026 |
0.364 |
|
| 2013 |
Sampath D, Oeh J, Xiao Y, Liang X, Vanderbilt A, Qin A, Yang L, Lee L, Ly J, Cosino E, LaCap J, Ogasawara A, Williams S, Nannini M, Liederer B, et al. Abstract B154: Co-administration of nicotinic acid with NAMPT small molecule inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B154 |
0.347 |
|
| 2012 |
Blake JF, Xu R, Bencsik JR, Xiao D, Kallan NC, Schlachter S, Mitchell IS, Spencer KL, Banka AL, Wallace EM, Gloor SL, Martinson M, Woessner RD, Vigers GP, Brandhuber BJ, ... ... Liederer BM, et al. Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors. Journal of Medicinal Chemistry. 55: 8110-27. PMID 22934575 DOI: 10.1021/Jm301024W |
0.336 |
|
| 2012 |
Liu X, Ding X, Deshmukh G, Liederer BM, Hop CE. Use of the cassette-dosing approach to assess brain penetration in drug discovery. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 963-9. PMID 22328585 DOI: 10.1124/Dmd.111.044420 |
0.319 |
|
| 2012 |
Liederer BM, Liu X, Berezhkovskiy LM, Cain G, Ding X, Gaudino J, Kaus R, Plise EG, Sutherlin DP, Harstad EB. Preclinical stereoselective disposition and toxicokinetics of two novel MET inhibitors. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 42: 456-65. PMID 22122353 DOI: 10.3109/00498254.2011.632697 |
0.327 |
|
| 2011 |
Liang X, Yang L, Berezhkovskiy L, Liederer B, Nguyen T, Jia W, Schweiger M, Dean B, Deng Y. Evaluation of dried blood spot sampling following cassette dosing in drug discovery. Bioanalysis. 3: 2291-302. PMID 22011177 DOI: 10.4155/Bio.11.205 |
0.308 |
|
| 2011 |
Liang X, Ubhayakar S, Liederer BM, Dean B, Ran-Ran Qin A, Shahidi-Latham S, Deng Y. Evaluation of homogenization techniques for the preparation of mouse tissue samples to support drug discovery. Bioanalysis. 3: 1923-33. PMID 21899502 DOI: 10.4155/Bio.11.181 |
0.317 |
|
| 2011 |
Liederer BM, Berezhkovskiy LM, Dean BJ, Dinkel V, Peng J, Merchant M, Plise EG, Wong H, Liu X. Preclinical absorption, distribution, metabolism, excretion, and pharmacokinetic-pharmacodynamic modelling of N-(4-(3-((3S,4R)-1-ethyl-3-fluoropiperidine-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorophenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide, a novel MET kinase inhibitor. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 41: 327-39. PMID 21182395 DOI: 10.3109/00498254.2010.542500 |
0.364 |
|
| 2011 |
Yan Y, Wagle M, Punnoose E, Musib L, Budha N, Nannini M, Lin K, Liederer BM, Murli S, Ramakrishnan V, Patel P, Cervantes A, Tabernero J. Abstract B154: A first-in-human trial of GDC-0068: A novel, oral, ATP-competitive Akt inhibitor, demonstrates robust suppression of the Akt pathway in surrogate and tumor tissues. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-B154 |
0.359 |
|
| 2009 |
Choo EF, Driscoll JP, Feng J, Liederer B, Plise E, Randolph N, Shin Y, Wong S, Ran Y. Disposition of GDC-0879, a B-RAF kinase inhibitor in preclinical species. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 39: 700-9. PMID 19552528 DOI: 10.1080/00498250902991827 |
0.31 |
|
| 2006 |
Liederer BM, Borchardt RT. Enzymes involved in the bioconversion of ester-based prodrugs. Journal of Pharmaceutical Sciences. 95: 1177-95. PMID 16639719 DOI: 10.1002/Jps.20542 |
0.427 |
|
| 2006 |
Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT. Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. Journal of Medicinal Chemistry. 49: 1261-70. PMID 16480263 DOI: 10.1021/Jm050277F |
0.457 |
|
| 2005 |
Liederer BM, Phan KT, Ouyang H, Borchardt RT. Significant differences in the disposition of cyclic prodrugs of opioid peptides in rats and guinea pigs following IV administration. Journal of Pharmaceutical Sciences. 94: 2676-87. PMID 16258984 DOI: 10.1002/Jps.20476 |
0.484 |
|
| 2005 |
Liederer BM, Borchardt RT. Stability of oxymethyl-modified coumarinic acid cyclic prodrugs of diastereomeric opioid peptides in biological media from various animal species including human. Journal of Pharmaceutical Sciences. 94: 2198-206. PMID 16136552 DOI: 10.1002/Jps.20452 |
0.469 |
|
| Show low-probability matches. |